Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019:22 de mayo. [Ref.ID 103124]

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019;42:abril. [Ref.ID 103082]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J, Brevik C, Williamson K, Abbott D. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019:26 de marzo. [Ref.ID 103069]

Anónimo. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). U.S. Food and Drug Administration 2019:21 de febrero. [Ref.ID 103045]

Huang S-P, Wen Y-C, Huang S-T, Lin C-W, Wang T-D, Hsiao F-Y. Nonsteroidal anti-inflammatory drugs and risk of first hospitalization for heart failure in patients with no history of heart failure: a population-based case-crossover study. Drug Saf 2019;42:enero. [Ref.ID 103029]

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:3 de enero. [Ref.ID 102994]

Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]

Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, Manson JE. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. Menopause 2018:17 de diciembre. [Ref.ID 102910]

Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]

Girard TD , Exline MC , Carson SS , Hough CL , Rock P , Gong MN , Douglas IS , Malhotra A , Owens RL , Feinstein DJ , Khan B , Pisani MA , Hyzy RC , Schmidt GA , Schweickert WD , Hite RD , Bowton DL , Masica AL , Thompson JL , Chandrasekhar R , Pun BT , Strength C , Boehm LM , Jackson JC , Pandharipande PP , Brummel NE , Hughes CG , Patel MB , Stollings JL , Bernard GR , Dittus RS , Ely EW , for the MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in vritical illness. N Engl J Med 2018;379:22 de octubre. [Ref.ID 102838]

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]

Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis 2018;77:agosto. [Ref.ID 102825]

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]

Chuang S-Y, Hsu P-F, Lin F-J, Huang Y-W, Wang G-Z, Chang W-C, Tsai H-J. Association between nonsteroidal anti-inflammatory drugs and atrial fibrillation among a middle-aged population: a nationwide population-based cohort. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102805]

Baillargeon J, Kuo YF, Westra JR, Urban RJ, Goodwin JS. Testosterone prescribing in the United States, 2002-2016. JAMA 2018;319:10 de julio. [Ref.ID 102792]

El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A. Characteristics of tianeptine exposures reported to the National Poison Data System — United States, 2000–2017. Morbidity and Mortality Weekly Report 2018;67:3 de agosto. [Ref.ID 102752]

Anónimo. Public Citizen asks FDA to take gout drug off market due to cardiovascular risks. DIA Daily 2018:5. [Ref.ID 102701]

Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]

Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]